https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Aptevo_Therapeutics_IncAptevo Therapeutics Inc - Revizia istoricului2026-04-25T21:53:54ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Aptevo_Therapeutics_Inc&diff=406889&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Aptevo Therapeutics Inc listata cu simbolul US.APVO ==Descriere companie== Aptevo Therapeutics Inc. (www.aptevotherapeutics.com) is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific an...2024-09-18T13:38:28Z<p>Pagină nouă: Pagina dedicata companiei Aptevo Therapeutics Inc listata cu simbolul US.APVO ==Descriere companie== Aptevo Therapeutics Inc. (www.aptevotherapeutics.com) is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific an...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Aptevo Therapeutics Inc listata cu simbolul US.APVO<br />
<br />
==Descriere companie==<br />
Aptevo Therapeutics Inc. (www.aptevotherapeutics.com) is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multi-specific antibody candidates that are capable for the human immune system against cancer cells. The Company's lead product candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using the ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using the ADAPTIR-FLEX modular protein technology platform. APVO436 is a recombinant, bispecific T-cell engaging antibody candidate that is designed to target CD123, CD3 and redirect T-cell cytotoxicity to the tumor.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.APVO" /><br />
<br />
==Ultimele stiri despre Aptevo Therapeutics Inc (US.APVO)==<br />
<dynamicpagelist><br />
category=US.APVO<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.APVO]][[Categorie:Stiri despre companii]]</div>Admin